Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma

Chad M. McKee, Danmei Xu, Yunhong Cao, Sheheryar Kabraji, Danny Allen, Veerle Kersemans, John Beech, Sean Smart, Freddie Hamdy, Adrian Ishkanian, Jenna Sykes, Melania Pintile, Michael Milosevic, Theodorus Van Der Kwast, Gaetano Zafarana, Varune Rohan Ramnarine, Igor Jurisica, Chad Mallof, Wan Lam, Robert G. Bristow & 1 others Ruth J. Muschel

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Prostate adenocarcinoma (CaP) patients are classified into low-, intermediate-, and high-risk groups that reflect relative survival categories. While there are accepted treatment regimens for low- and high-risk patients, intermediate-risk patients pose a clinical dilemma, as treatment outcomes are highly variable for these individuals. A better understanding of the factors that regulate the progression of CaP is required to delineate risk. For example, aberrant activation of the Hedgehog (Hh) pathway is implicated in CaP progression. Here, we identify the serine protease inhibitor protease nexin 1 (PN1) as a negative regulator of Hh signaling in prostate. Using human CaP cell lines and a mouse xenograft model of CaP, we demonstrate that PN1 regulates Hh signaling by decreasing protein levels of the Hh ligand Sonic (SHH) and its downstream effectors. Furthermore, we show that SHH expression enhanced tumor growth while overexpression of PN1 inhibited tumor growth and angiogenesis in mice. Finally, using comparative genome hybridization, we found that genetic alterations in Hh pathway genes correlated with worse clinical outcomes in intermediate-risk CaP patients, indicating the importance of this pathway in CaP.

Original languageEnglish (US)
Pages (from-to)4025-4036
Number of pages12
JournalJournal of Clinical Investigation
Volume122
Issue number11
DOIs
StatePublished - Nov 1 2012
Externally publishedYes

Fingerprint

Protease Nexins
Hedgehogs
Prostate
Adenocarcinoma
Hedgehog Proteins
Serine Proteinase Inhibitors
Comparative Genomic Hybridization
Growth
Heterografts
Neoplasms
Ligands
Cell Line
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

McKee, C. M., Xu, D., Cao, Y., Kabraji, S., Allen, D., Kersemans, V., ... Muschel, R. J. (2012). Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. Journal of Clinical Investigation, 122(11), 4025-4036. https://doi.org/10.1172/JCI59348

Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. / McKee, Chad M.; Xu, Danmei; Cao, Yunhong; Kabraji, Sheheryar; Allen, Danny; Kersemans, Veerle; Beech, John; Smart, Sean; Hamdy, Freddie; Ishkanian, Adrian; Sykes, Jenna; Pintile, Melania; Milosevic, Michael; Van Der Kwast, Theodorus; Zafarana, Gaetano; Ramnarine, Varune Rohan; Jurisica, Igor; Mallof, Chad; Lam, Wan; Bristow, Robert G.; Muschel, Ruth J.

In: Journal of Clinical Investigation, Vol. 122, No. 11, 01.11.2012, p. 4025-4036.

Research output: Contribution to journalArticle

McKee, CM, Xu, D, Cao, Y, Kabraji, S, Allen, D, Kersemans, V, Beech, J, Smart, S, Hamdy, F, Ishkanian, A, Sykes, J, Pintile, M, Milosevic, M, Van Der Kwast, T, Zafarana, G, Ramnarine, VR, Jurisica, I, Mallof, C, Lam, W, Bristow, RG & Muschel, RJ 2012, 'Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma', Journal of Clinical Investigation, vol. 122, no. 11, pp. 4025-4036. https://doi.org/10.1172/JCI59348
McKee CM, Xu D, Cao Y, Kabraji S, Allen D, Kersemans V et al. Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. Journal of Clinical Investigation. 2012 Nov 1;122(11):4025-4036. https://doi.org/10.1172/JCI59348
McKee, Chad M. ; Xu, Danmei ; Cao, Yunhong ; Kabraji, Sheheryar ; Allen, Danny ; Kersemans, Veerle ; Beech, John ; Smart, Sean ; Hamdy, Freddie ; Ishkanian, Adrian ; Sykes, Jenna ; Pintile, Melania ; Milosevic, Michael ; Van Der Kwast, Theodorus ; Zafarana, Gaetano ; Ramnarine, Varune Rohan ; Jurisica, Igor ; Mallof, Chad ; Lam, Wan ; Bristow, Robert G. ; Muschel, Ruth J. / Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. In: Journal of Clinical Investigation. 2012 ; Vol. 122, No. 11. pp. 4025-4036.
@article{6f9863e65ab040d5b6edf81de110f42c,
title = "Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma",
abstract = "Prostate adenocarcinoma (CaP) patients are classified into low-, intermediate-, and high-risk groups that reflect relative survival categories. While there are accepted treatment regimens for low- and high-risk patients, intermediate-risk patients pose a clinical dilemma, as treatment outcomes are highly variable for these individuals. A better understanding of the factors that regulate the progression of CaP is required to delineate risk. For example, aberrant activation of the Hedgehog (Hh) pathway is implicated in CaP progression. Here, we identify the serine protease inhibitor protease nexin 1 (PN1) as a negative regulator of Hh signaling in prostate. Using human CaP cell lines and a mouse xenograft model of CaP, we demonstrate that PN1 regulates Hh signaling by decreasing protein levels of the Hh ligand Sonic (SHH) and its downstream effectors. Furthermore, we show that SHH expression enhanced tumor growth while overexpression of PN1 inhibited tumor growth and angiogenesis in mice. Finally, using comparative genome hybridization, we found that genetic alterations in Hh pathway genes correlated with worse clinical outcomes in intermediate-risk CaP patients, indicating the importance of this pathway in CaP.",
author = "McKee, {Chad M.} and Danmei Xu and Yunhong Cao and Sheheryar Kabraji and Danny Allen and Veerle Kersemans and John Beech and Sean Smart and Freddie Hamdy and Adrian Ishkanian and Jenna Sykes and Melania Pintile and Michael Milosevic and {Van Der Kwast}, Theodorus and Gaetano Zafarana and Ramnarine, {Varune Rohan} and Igor Jurisica and Chad Mallof and Wan Lam and Bristow, {Robert G.} and Muschel, {Ruth J.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1172/JCI59348",
language = "English (US)",
volume = "122",
pages = "4025--4036",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "11",

}

TY - JOUR

T1 - Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma

AU - McKee, Chad M.

AU - Xu, Danmei

AU - Cao, Yunhong

AU - Kabraji, Sheheryar

AU - Allen, Danny

AU - Kersemans, Veerle

AU - Beech, John

AU - Smart, Sean

AU - Hamdy, Freddie

AU - Ishkanian, Adrian

AU - Sykes, Jenna

AU - Pintile, Melania

AU - Milosevic, Michael

AU - Van Der Kwast, Theodorus

AU - Zafarana, Gaetano

AU - Ramnarine, Varune Rohan

AU - Jurisica, Igor

AU - Mallof, Chad

AU - Lam, Wan

AU - Bristow, Robert G.

AU - Muschel, Ruth J.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Prostate adenocarcinoma (CaP) patients are classified into low-, intermediate-, and high-risk groups that reflect relative survival categories. While there are accepted treatment regimens for low- and high-risk patients, intermediate-risk patients pose a clinical dilemma, as treatment outcomes are highly variable for these individuals. A better understanding of the factors that regulate the progression of CaP is required to delineate risk. For example, aberrant activation of the Hedgehog (Hh) pathway is implicated in CaP progression. Here, we identify the serine protease inhibitor protease nexin 1 (PN1) as a negative regulator of Hh signaling in prostate. Using human CaP cell lines and a mouse xenograft model of CaP, we demonstrate that PN1 regulates Hh signaling by decreasing protein levels of the Hh ligand Sonic (SHH) and its downstream effectors. Furthermore, we show that SHH expression enhanced tumor growth while overexpression of PN1 inhibited tumor growth and angiogenesis in mice. Finally, using comparative genome hybridization, we found that genetic alterations in Hh pathway genes correlated with worse clinical outcomes in intermediate-risk CaP patients, indicating the importance of this pathway in CaP.

AB - Prostate adenocarcinoma (CaP) patients are classified into low-, intermediate-, and high-risk groups that reflect relative survival categories. While there are accepted treatment regimens for low- and high-risk patients, intermediate-risk patients pose a clinical dilemma, as treatment outcomes are highly variable for these individuals. A better understanding of the factors that regulate the progression of CaP is required to delineate risk. For example, aberrant activation of the Hedgehog (Hh) pathway is implicated in CaP progression. Here, we identify the serine protease inhibitor protease nexin 1 (PN1) as a negative regulator of Hh signaling in prostate. Using human CaP cell lines and a mouse xenograft model of CaP, we demonstrate that PN1 regulates Hh signaling by decreasing protein levels of the Hh ligand Sonic (SHH) and its downstream effectors. Furthermore, we show that SHH expression enhanced tumor growth while overexpression of PN1 inhibited tumor growth and angiogenesis in mice. Finally, using comparative genome hybridization, we found that genetic alterations in Hh pathway genes correlated with worse clinical outcomes in intermediate-risk CaP patients, indicating the importance of this pathway in CaP.

UR - http://www.scopus.com/inward/record.url?scp=84868629685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868629685&partnerID=8YFLogxK

U2 - 10.1172/JCI59348

DO - 10.1172/JCI59348

M3 - Article

VL - 122

SP - 4025

EP - 4036

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 11

ER -